Lv4
440 积分 2023-05-08 加入
Optimizing local control in the surgical management of bladder cancer
2个月前
已完结
[Immune checkpoint inhibitors-related hyperprogressive disease: a case report]
2个月前
已完结
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
2个月前
已完结
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
2个月前
已完结
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
3个月前
已完结
[Progress on the research of liver diseases in 2022]
5个月前
已完结
Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness
5个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
5个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
5个月前
已完结
Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study
6个月前
已完结
皖公网安备34019202002308
